ATE450526T1 - Als antagonisten von histamin h3 geeignete piperidinderivate - Google Patents
Als antagonisten von histamin h3 geeignete piperidinderivateInfo
- Publication number
- ATE450526T1 ATE450526T1 AT06773528T AT06773528T ATE450526T1 AT E450526 T1 ATE450526 T1 AT E450526T1 AT 06773528 T AT06773528 T AT 06773528T AT 06773528 T AT06773528 T AT 06773528T AT E450526 T1 ATE450526 T1 AT E450526T1
- Authority
- AT
- Austria
- Prior art keywords
- histamine
- antagonists
- piperidine derivatives
- derivatives suitable
- piperidine
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229960001340 histamine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69211005P | 2005-06-20 | 2005-06-20 | |
| PCT/US2006/023800 WO2007001975A1 (en) | 2005-06-20 | 2006-06-19 | Piperidine derivatives useful as histamine h3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE450526T1 true ATE450526T1 (de) | 2009-12-15 |
Family
ID=36968725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06773528T ATE450526T1 (de) | 2005-06-20 | 2006-06-19 | Als antagonisten von histamin h3 geeignete piperidinderivate |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7635705B2 (de) |
| EP (1) | EP1902046B1 (de) |
| JP (1) | JP2008546784A (de) |
| KR (1) | KR20080021082A (de) |
| CN (1) | CN101243072A (de) |
| AR (1) | AR054787A1 (de) |
| AT (1) | ATE450526T1 (de) |
| AU (1) | AU2006262441A1 (de) |
| CA (1) | CA2610959A1 (de) |
| DE (1) | DE602006010870D1 (de) |
| ES (1) | ES2337727T3 (de) |
| IL (1) | IL187984A0 (de) |
| MX (1) | MX2008000115A (de) |
| TW (1) | TW200738676A (de) |
| WO (1) | WO2007001975A1 (de) |
| ZA (1) | ZA200710968B (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| JP2009521445A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ |
| US20080221100A1 (en) * | 2006-10-20 | 2008-09-11 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| MX2009008073A (es) * | 2007-01-29 | 2009-08-12 | Arete Therapeutics Inc | Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados. |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| TW200840571A (en) * | 2007-03-02 | 2008-10-16 | Schering Corp | Piperidine derivatives and methods of use thereof |
| EP2132176A1 (de) * | 2007-03-13 | 2009-12-16 | Arete Therapeutics, Inc. | 4-piperidinylharnstoffverbindungen als lösliche epoxidhydrolaseinhibitoren |
| MX2009011416A (es) | 2007-04-23 | 2009-11-05 | Janssen Pharmaceutica Nv | Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. |
| CA2683111A1 (en) | 2007-04-23 | 2008-10-30 | Janssen Pharmaceutica N.V. | 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists |
| JP2010527915A (ja) * | 2007-04-26 | 2010-08-19 | アバロン ファーマシューティカルズ，インコーポレイテッド | 多重環化合物及びその用途 |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| JP5417439B2 (ja) | 2008-07-03 | 2014-02-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類 |
| EP2318388A2 (de) | 2008-07-23 | 2011-05-11 | Schering Corporation | Tricyclische spirocyclusderivate und verfahren zu deren verwendung |
| CN102171189B (zh) | 2008-07-31 | 2013-11-20 | 詹森药业有限公司 | 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶 |
| US8889674B2 (en) | 2009-03-05 | 2014-11-18 | Shionogi & Co., Ltd. | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism |
| US8337835B2 (en) * | 2009-04-10 | 2012-12-25 | Washington University | Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders |
| PH12012501385A1 (en) | 2010-01-22 | 2014-10-22 | Taiho Pharmaceutical Co Ltd | Piperazine compound having a pgds inhibitory effect |
| EP2575815A4 (de) | 2010-06-04 | 2013-12-25 | Albany Molecular Res Inc | Glycin-transporter-1-hemmer, verfahren zu ihrer herstellung und ihre verwendung |
| EP2661421A2 (de) * | 2011-01-07 | 2013-11-13 | Targacept, Inc. | Nichtkompetitive antagonisten des nikotinrezeptors |
| US8865641B2 (en) * | 2011-06-16 | 2014-10-21 | The Feinstein Institute For Medical Research | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways |
| BR112014006220A2 (pt) | 2011-09-16 | 2017-04-11 | Galectin Therapeutics Inc | composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| CN102657868A (zh) * | 2012-05-30 | 2012-09-12 | 中国药科大学 | 5-羟色胺2受体拮抗剂或转运体抑制剂治疗脂肪肝或高脂血症 |
| CN104619329B (zh) | 2012-06-06 | 2018-01-26 | 卡莱克汀医疗有限公司 | 用于治疗与升高的诱导型一氧化氮合酶相关联的疾病的半乳糖‑鼠李糖半乳糖醛酸酯组合物 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN109082465A (zh) * | 2018-08-20 | 2018-12-25 | 苏州市广济医院 | 奥氮平诱导糖代谢紊乱相关疾病的分子标志物及其用途 |
| CN114072407A (zh) | 2019-04-02 | 2022-02-18 | 阿里戈斯治疗公司 | 靶向prmt5的化合物 |
| WO2021187605A1 (ja) * | 2020-03-19 | 2021-09-23 | 田辺三菱製薬株式会社 | 含窒素複素環αシアノカルボニル化合物 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US661145A (en) * | 1900-08-06 | 1900-11-06 | Otto Hausmann | Attachment for bicycles. |
| US856473A (en) * | 1906-05-21 | 1907-06-11 | Daniel E Krause | Drilling-machine. |
| US4983567A (en) * | 1987-03-16 | 1991-01-08 | Biomeasure, Inc. | Immunomodulators and methods of making same |
| US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
| CZ14294A3 (en) | 1991-07-23 | 1994-07-13 | Schering Corp | Substituted beta-lactam compounds usable as hypocholesterol pharmaceutical preparations and process for preparing thereof |
| US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| US5688785A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| PT707567E (pt) | 1993-07-09 | 2002-01-30 | Schering Corp | Processo de sintese de azetidinonas |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5627176A (en) | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5618707A (en) | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
| AU7472896A (en) | 1995-11-02 | 1997-05-22 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon |
| US5739321A (en) | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
| US5886171A (en) | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
| PE100298A1 (es) | 1996-08-16 | 1999-01-11 | Schering Corp | Tratamiento de las respuestas alergicas de la vias respiratorias superiores |
| US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| US6133001A (en) | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
| CA2333554A1 (en) * | 1998-06-17 | 1999-12-23 | Chu-Baio Xue | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US5919672A (en) | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
| US6207822B1 (en) | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
| WO2000063703A1 (en) | 1999-04-16 | 2000-10-26 | Schering Corporation | Use of azetidinone compounds |
| EA200200847A1 (ru) * | 2000-02-11 | 2003-02-27 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов |
| US20020045686A1 (en) | 2000-08-24 | 2002-04-18 | The Yokohama Rubber Co., Ltd | Rubber composition having improved wet skid resistance and rolling resistance |
| DE10042447A1 (de) | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
| PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| IL156548A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| IL156552A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| AU1609702A (en) | 2000-12-21 | 2002-07-01 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| MXPA03008356A (es) | 2001-03-13 | 2003-12-11 | Schering Corp | Compuestos del tipo no imidazol como antagonistas de histamina h3. |
| EA006898B1 (ru) | 2001-03-28 | 2006-04-28 | Шеринг Корпорейшн | Энантиоселективный синтез промежуточных соединений для получения азетидинонов |
| US20030137689A1 (en) * | 2002-01-18 | 2003-07-24 | General Instrument Corporation. | Remote printer driver server |
| DK1499316T3 (da) * | 2002-04-18 | 2008-07-21 | Schering Corp | (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister |
| KR20040099449A (ko) | 2002-04-18 | 2004-11-26 | 쉐링 코포레이션 | 히스타민 ｈ3 길항제로서의1-(4-피페리디닐)벤즈이미다졸론 |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| DE10227506A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE10227508A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE10227507A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| EP1539742B1 (de) | 2002-06-24 | 2006-11-08 | Schering Corporation | Als histamin-h3-antagonisten geeignete indolderivate |
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| MXPA05001264A (es) | 2002-08-06 | 2005-04-28 | Aventis Pharma Gmbh | Metodos para aislar una proteina intenstinal que se une al colesterol. |
| US20040198743A1 (en) | 2003-01-31 | 2004-10-07 | Schering Corporation | Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists |
| CN100439361C (zh) | 2003-03-07 | 2008-12-03 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| CN1756755A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
| GB0308333D0 (en) | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| DE602004015269D1 (de) | 2003-04-23 | 2008-09-04 | Glaxo Group Ltd | Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten. |
| US20040224952A1 (en) | 2003-05-07 | 2004-11-11 | Cowart Marlon D. | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
| JP2005015434A (ja) | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
| GB0315360D0 (en) | 2003-07-01 | 2003-08-06 | Burns Robert N | Anti-theft device |
| AU2003259547A1 (en) | 2003-07-31 | 2005-02-14 | Hetero Drugs Limited | Ezetimibe polymorphs |
| WO2005021495A2 (en) | 2003-08-25 | 2005-03-10 | Microbia Inc. | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
| US20070161577A1 (en) | 2003-08-28 | 2007-07-12 | Martinez Eduardo J | Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones |
| GB0321228D0 (en) | 2003-09-10 | 2003-10-08 | Inpharmatica Ltd | Modulating cell activity |
| JP2007524651A (ja) | 2003-09-26 | 2007-08-30 | フォーブス メディ−テック インコーポレーテッド | 多剤耐性遺伝子の発現を抑制して、該遺伝子の発現によって生じるタンパク質の製造を抑制し、それにより、癌治療のための化学療法薬の有効性を高める方法。 |
| EP1522541A1 (de) | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Neue hypocholesterolemische Verbindungen |
| WO2005044256A1 (en) | 2003-10-30 | 2005-05-19 | Merck & Co., Inc. | 2-azetidinones as anti-hypercholesterolemic agents |
| WO2005042692A2 (en) | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
| JP4839221B2 (ja) | 2003-11-07 | 2011-12-21 | ジェイ ジェイ ファーマ，インコーポレイテッド | Ｈｄｌを高める併用療法用複合物 |
| CA2545058A1 (en) | 2003-11-10 | 2005-05-26 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
| GB0329778D0 (en) | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| EP1699760B1 (de) | 2003-12-23 | 2017-05-17 | Merck Sharp & Dohme Corp. | Antihypercholesterinämische verbindungen |
| CA2550215A1 (en) | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
-
2006
- 2006-06-19 EP EP06773528A patent/EP1902046B1/de active Active
- 2006-06-19 MX MX2008000115A patent/MX2008000115A/es active IP Right Grant
- 2006-06-19 KR KR1020077030855A patent/KR20080021082A/ko not_active Withdrawn
- 2006-06-19 CA CA002610959A patent/CA2610959A1/en not_active Abandoned
- 2006-06-19 DE DE602006010870T patent/DE602006010870D1/de active Active
- 2006-06-19 JP JP2008518276A patent/JP2008546784A/ja not_active Withdrawn
- 2006-06-19 TW TW095121918A patent/TW200738676A/zh unknown
- 2006-06-19 ES ES06773528T patent/ES2337727T3/es active Active
- 2006-06-19 AU AU2006262441A patent/AU2006262441A1/en not_active Abandoned
- 2006-06-19 CN CNA2006800301178A patent/CN101243072A/zh active Pending
- 2006-06-19 WO PCT/US2006/023800 patent/WO2007001975A1/en not_active Ceased
- 2006-06-19 AT AT06773528T patent/ATE450526T1/de not_active IP Right Cessation
- 2006-06-19 US US11/455,625 patent/US7635705B2/en not_active Expired - Fee Related
- 2006-06-20 AR ARP060102617A patent/AR054787A1/es not_active Application Discontinuation
-
2007
- 2007-12-06 IL IL187984A patent/IL187984A0/en unknown
- 2007-12-18 ZA ZA200710968A patent/ZA200710968B/xx unknown
-
2009
- 2009-07-22 US US12/507,563 patent/US7846946B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1902046A1 (de) | 2008-03-26 |
| CN101243072A (zh) | 2008-08-13 |
| US20070015807A1 (en) | 2007-01-18 |
| CA2610959A1 (en) | 2007-01-04 |
| WO2007001975A8 (en) | 2008-01-24 |
| US7635705B2 (en) | 2009-12-22 |
| EP1902046B1 (de) | 2009-12-02 |
| HK1121737A1 (en) | 2009-04-30 |
| WO2007001975A1 (en) | 2007-01-04 |
| TW200738676A (en) | 2007-10-16 |
| AU2006262441A1 (en) | 2007-01-04 |
| KR20080021082A (ko) | 2008-03-06 |
| ES2337727T3 (es) | 2010-04-28 |
| US20090286830A1 (en) | 2009-11-19 |
| JP2008546784A (ja) | 2008-12-25 |
| ZA200710968B (en) | 2009-03-25 |
| AR054787A1 (es) | 2007-07-18 |
| MX2008000115A (es) | 2008-03-18 |
| US7846946B2 (en) | 2010-12-07 |
| IL187984A0 (en) | 2008-03-20 |
| DE602006010870D1 (de) | 2010-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE450526T1 (de) | Als antagonisten von histamin h3 geeignete piperidinderivate | |
| ATE344798T1 (de) | Als histamin-h3-antagonisten geeignete indolderivate | |
| ATE494287T1 (de) | Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase | |
| DE602006015607D1 (de) | Thiazol-4-carboxamid-derivate als mglur5-antagonisten | |
| ATE452635T1 (de) | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer | |
| ATE520671T1 (de) | Pyrimidin-harnstoff-derivate als kinase-hemmer | |
| ATE521607T1 (de) | Piperidinderivate als renin-inhibitoren | |
| DE60331751D1 (de) | N-substituierte 2-oxodihydropyridinderivate als npy antagonisten | |
| ATE404564T1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| ATE448217T1 (de) | Substituierte piperidine als renin-inhibitoren | |
| ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
| ATE524467T1 (de) | Neuartige aza-heterozyklen als kinase-inhibitoren | |
| DE60319813D1 (de) | 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten | |
| DE602004025258D1 (de) | Aminotriazol-verbindungen als proteinkinase-hemmer | |
| DE60320529D1 (de) | Chinolinderivate als npy antagonisten | |
| DE602006008945D1 (de) | Isochinolinderivate als inhibitoren von rho-kinase | |
| ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
| ATE414698T1 (de) | Durch 5gliedrige heterocyclen substituierte mtp- inhibierende arylpiperidine oder -piperazine | |
| ATE530545T1 (de) | Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate | |
| ATE394391T1 (de) | Indolderivate als histaminrezeptorantagonisten | |
| ATE449091T1 (de) | Substituierte triazolderivate als oxytocinantagonisten | |
| ATE370135T1 (de) | Substituierte piperidine als histamin-h3- rezeptorliganden | |
| DE602006019624D1 (de) | Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors | |
| ATE509011T1 (de) | Pyrimidinderivate als 11beta-hsd1-inhibitoren | |
| DE602005014646D1 (de) | Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |